A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
I5B-MC-JGDN - ClinicalTrials.gov - NCT02677116
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given alone for 21 days and followed by one of three standard chemotherapy regimens. Participants will enroll in one part only.
Trial Summary
Age Range
≤17 yearsConditions the trial is for
Pediatric Solid TumorsWhat the trial is testing?
Doxorubicin, Ifosfamide, Irinotecan, Olaratumab, VincristineCould I receive a Placebo?
NoEnrollment Goal
68Trial Dates
Aug 29, 2016 - Apr 3, 2019How long will I be in the trial?
Your participation could last up to 3 years depending on how you and your tumor respond.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo